197 related articles for article (PubMed ID: 34257283)
1. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells.
Chen WC; To MD; Westcott PMK; Delrosario R; Kim IJ; Philips M; Tran Q; Bollam SR; Goodarzi H; Bayani N; Mirzoeva O; Balmain A
Nat Commun; 2021 Jul; 12(1):4288. PubMed ID: 34257283
[TBL] [Abstract][Full Text] [Related]
2. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M; Paniagua G; Lechuga CG; Fernández-García F; Zarzuela E; Álvarez-Díaz R; Musteanu M; Guerra C; Caleiras E; Muñoz J; Ortega S; Drosten M; Barbacid M
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301865
[TBL] [Abstract][Full Text] [Related]
3. Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.
Ting TC; Goralski M; Klein K; Wang B; Kim J; Xie Y; Nijhawan D
Cell Rep; 2019 Nov; 29(6):1499-1510.e6. PubMed ID: 31693891
[TBL] [Abstract][Full Text] [Related]
4. Differential functions of the KRAS splice variants.
Kochen Rossi J; Nuevo-Tapioles C; Philips MR
Biochem Soc Trans; 2023 Jun; 51(3):1191-1199. PubMed ID: 37222266
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
Bussiere DE; Xie L; Srinivas H; Shu W; Burke A; Be C; Zhao J; Godbole A; King D; Karki RG; Hornak V; Xu F; Cobb J; Carte N; Frank AO; Frommlet A; Graff P; Knapp M; Fazal A; Okram B; Jiang S; Michellys PY; Beckwith R; Voshol H; Wiesmann C; Solomon JM; Paulk J
Nat Chem Biol; 2020 Jan; 16(1):15-23. PubMed ID: 31819272
[TBL] [Abstract][Full Text] [Related]
6. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Han T; Goralski M; Gaskill N; Capota E; Kim J; Ting TC; Xie Y; Williams NS; Nijhawan D
Science; 2017 Apr; 356(6336):. PubMed ID: 28302793
[TBL] [Abstract][Full Text] [Related]
7. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Whitley MJ; Tran TH; Rigby M; Yi M; Dharmaiah S; Waybright TJ; Ramakrishnan N; Perkins S; Taylor T; Messing S; Esposito D; Nissley DV; McCormick F; Stephen AG; Turbyville T; Cornilescu G; Simanshu DK
Sci Adv; 2024 Feb; 10(7):eadj4137. PubMed ID: 38354232
[No Abstract] [Full Text] [Related]
9. KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab.
Chiari R; Palladino S; Emili R; De Lisa M; Sarti D; Catalano V; Magnani M; Graziano F; Ruzzo A
Sci Rep; 2023 Nov; 13(1):21036. PubMed ID: 38030703
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.
Du X; Volkov OA; Czerwinski RM; Tan H; Huerta C; Morton ER; Rizzi JP; Wehn PM; Xu R; Nijhawan D; Wallace EM
Structure; 2019 Nov; 27(11):1625-1633.e3. PubMed ID: 31693911
[TBL] [Abstract][Full Text] [Related]
11. Proximity Labeling, Quantitative Proteomics, and Biochemical Studies Revealed the Molecular Mechanism for the Inhibitory Effect of Indisulam on the Proliferation of Gastric Cancer Cells.
Lu J; Jiang H; Li D; Chen T; Wang Y; Pu Z; Xu G
J Proteome Res; 2021 Sep; 20(9):4462-4474. PubMed ID: 34420308
[TBL] [Abstract][Full Text] [Related]
12. The role of KRAS splice variants in cancer biology.
Nuevo-Tapioles C; Philips MR
Front Cell Dev Biol; 2022; 10():1033348. PubMed ID: 36393833
[TBL] [Abstract][Full Text] [Related]
13. Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.
Adams LM; DeHart CJ; Drown BS; Anderson LC; Bocik W; Boja ES; Hiltke TM; Hendrickson CL; Rodriguez H; Caldwell M; Vafabakhsh R; Kelleher NL
J Biol Chem; 2023 Jan; 299(1):102768. PubMed ID: 36470426
[TBL] [Abstract][Full Text] [Related]
14. KRAS4A directly regulates hexokinase 1.
Amendola CR; Mahaffey JP; Parker SJ; Ahearn IM; Chen WC; Zhou M; Court H; Shi J; Mendoza SL; Morten MJ; Rothenberg E; Gottlieb E; Wadghiri YZ; Possemato R; Hubbard SR; Balmain A; Kimmelman AC; Philips MR
Nature; 2019 Dec; 576(7787):482-486. PubMed ID: 31827279
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
16. Origin and Evolution of RAS Membrane Targeting.
García-España A; Philips MR
Oncogene; 2023 May; 42(21):1741-1750. PubMed ID: 37031342
[TBL] [Abstract][Full Text] [Related]
17. Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b.
Zhang X; Cao J; Miller SP; Jing H; Lin H
ACS Cent Sci; 2018 Jan; 4(1):71-80. PubMed ID: 29392178
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding motif protein 39 (RBM39): An emerging cancer target.
Xu Y; Nijhuis A; Keun HC
Br J Pharmacol; 2022 Jun; 179(12):2795-2812. PubMed ID: 33238031
[TBL] [Abstract][Full Text] [Related]
19. Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma.
Nijhuis A; Sikka A; Yogev O; Herendi L; Balcells C; Ma Y; Poon E; Eckold C; Valbuena GN; Xu Y; Liu Y; da Costa BM; Gruet M; Wickremesinghe C; Benito A; Kramer H; Montoya A; Carling D; Want EJ; Jamin Y; Chesler L; Keun HC
Nat Commun; 2022 Mar; 13(1):1380. PubMed ID: 35296644
[TBL] [Abstract][Full Text] [Related]
20. Ras protein abundance correlates with Ras isoform mutation patterns in cancer.
Hood FE; Sahraoui YM; Jenkins RE; Prior IA
Oncogene; 2023 Apr; 42(15):1224-1232. PubMed ID: 36864243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
